Related Experiment Video
Updated: Feb 10, 2026
Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
Published on: March 15, 2024
Importance of pancreatic exocrine dysfunction in patients with type 2 diabetes: A randomized crossover study
Björn Lindkvist1, Catarina Nilsson2, Mats Kvarnström2
1Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
Background:
Levels of faecal elastase-1 (FE-1), a marker of exocrine pancreatic function, are lower in patients with type 2 diabetes than without diabetes. We aimed to investigate the association between FE-1 and nutritional status, gastrointestinal symptoms, and lipid absorption.
Methods:
This randomized, open-label, crossover study included 315 patients with type 2 diabetes aged 18-70 years treated with oral antidiabetics, with HbA1c 6.5-9.0% and BMI 18-40 kg/m2. Assessments included levels of FE-1 and blood biomarkers of nutrition, and Bristol Stool Scale and Gastrointestinal Symptom Rating Scale (GSRS) scores. Plasma exposure of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) after oral administration of free omega-3 carboxylic acids or ethyl esters with breakfast was investigated in patients with low, intermediate, and normal FE-1 levels.
Results:
The prevalence of low and intermediate FE-1 levels was 5.2% and 4.9%, respectively. Bristol Stool Scale scores and mean values of GSRS Diarrhoea and Indigestion domain symptoms were similar across groups, but patients with low FE-1 were heavier and reported lower stool frequency. FE-1 levels correlated positively with plasma levels of amylase, lipase, 25-hydroxy vitamin D, and albumin. Mean EPA + DHA exposure was similarly higher after intake of free vs. esterified omega-3 fatty acids in all FE-1 groups.
Conclusions:
The prevalence of low FE-1 (<100 μg/g) as a measure of pancreatic exocrine insufficiency was infrequent in type 2 diabetes. Except for low plasma concentrations of EPA and 25-hydroxy vitamin D, type 2 diabetes patients with low FE-1 had no other signs of malabsorption or gastrointestinal disorders. Plasma levels of EPA and DHA after the intake of esterified versus free EPA and DHA did not correlate with FE-1 levels.
Trial Registration:
ClinicalTrials.gov NCT02370537.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
01:13Exocrine Glands: Types of Secretions
Serous glands produce watery secretions rich in digestive enzymes and proteins. The constituent cells of the serous gland have centrally located nuclei and eosinophilic secretory granules in the cytoplasm. The parotid gland is an example of a serous gland. It secretes saliva, which contains enzymes, such as lipases and...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:16Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
01:08Exocrine Glands: Methods of Secretion
Merocrine Secretion
Merocrine secretion is the most common type of exocrine secretion. The secretions are enclosed in vesicles and moved to the cell's apical surface, where the contents are released by exocytosis. For example, mucous, a watery secretion rich in the glycoprotein mucin, is a merocrine secretion. The eccrine...